DATSUN
voted
When Cathie Wood reflects on her career, she attributes any professional marginalization she experiences to her contrarian views rather than her gender, she told CNBC in a recent interview.
By being unwavering and publicly vocal about her convictions, Wood gives critics ample opportunity to take aim at her unique strategies.
“Other people say that I am attacked in the media because I’m a woman. I don’t th...
By being unwavering and publicly vocal about her convictions, Wood gives critics ample opportunity to take aim at her unique strategies.
“Other people say that I am attacked in the media because I’m a woman. I don’t th...
![Cathie Wood has been a magnet for criticism. She blames her contrarian views, not her gender](https://ussnsimg.moomoo.com/1648621697059-70040979-android-org.png/thumb)
16
4
DATSUN
commented on
DATSUN
commented on
$NIO Inc (NIO.US)$ 以介绍形式上市到底是好消息还是坏消息呢,有懂的朋友解答一下吗
2
DATSUN
commented on
DATSUN
commented on
$NIO Inc (NIO.US)$ It was shipped at @$48.15. As retail investors, we'd better not chase higher
Translated
1
3
DATSUN
voted
$NIO Inc (NIO.US)$
There may be a few companies fighting to gain market share in China. I have faith that NIO will be one of the leading company taking a huge portion of the EV market.
What do you think?
There may be a few companies fighting to gain market share in China. I have faith that NIO will be one of the leading company taking a huge portion of the EV market.
What do you think?
11
2
DATSUN
commented on
DATSUN
voted
Key Takeaway:
● We are now informed that the FDA expects to assign our file to a reviewer and place it under review no later than April 15.
● A key business objective for us this year is to complete the IDE submission for this 365-day sensor, all subject to the availability of the FDA review group.
● We believe that we are now well positioned to address the top unmet need in the large and growing CGM market.
...
● We are now informed that the FDA expects to assign our file to a reviewer and place it under review no later than April 15.
● A key business objective for us this year is to complete the IDE submission for this 365-day sensor, all subject to the availability of the FDA review group.
● We believe that we are now well positioned to address the top unmet need in the large and growing CGM market.
...
6